Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 5, 2008 - Issue 2
Submit an article Journal homepage
420
Views
30
CrossRef citations to date
0
Altmetric
Review

Drug delivery and formulations for the topical treatment of psoriasis

Yu-Han Su Investigator of pharmaceutics Chang Gung University, Pharmaceutics Laboratory, Graduate Institute of Natural Products, 259 Wen-Hwa 1st Road, Kweishan, Taoyuan 333, Taiwan
&
Jia-You Fang Professor Chang Gung University, Pharmaceutics Laboratory, Graduate Institute of Natural Products, 259 Wen-Hwa 1st Road, Kweishan, Taoyuan 333, Taiwan +886 3 211 8800; +886 3 211 8236; [email protected]
, PhD
Pages 235-249 | Published online: 05 Feb 2008

Bibliography

  • Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet 1998;7:1537-45
  • Chrustopothers E, Mrowietz U. Psoriasis. In: Freedberg IM, Eisen AZ, Wolff K, editors. Fitzpatrick's Dermalology in General Medicine. Volume 1. 5th edition. New York: McGraw-Hill; 1999
  • Witman PM. Topical therapies for localized psoriasis. Mayo Clin Proc 2001;76:943-9
  • Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998;61:11-21
  • Fang JY, Leu YL. Prodrug strategy for enhancing drug delivery via skin. Curr Drug Discov Technol 2006;3:211-24
  • Bouwstra JA, Honeywell-Nguyen PL. Skin structure and mode of action of vesicles. Adv Drug Deliv Rev 2002;54(Suppl 1):S41-55
  • Asbill CS, El-Kattan AF, Michniak B. Enhancement of transdermal drug delivery: chemical and physical approaches. Crit Rev Ther Drug Carrier Syst 2000;17:621-58
  • Schatzlein A, Cevc G. Non-uniform cellular packing of the stratum corneum and permeability barrier function of intact skin: a high-resolution confocal laser scanning microscopy study using highly deformable vesicles (Transfersomes). Br J Dermatol 1998;138:583-92
  • Cevc G, Schatzlein A, Richardsen H. Ultradeformable lipid vesicles can penetrate the skin and other semi-permeable barriers unfragmented. Evidence from double label CLSM experiments and direct size measurements. Biochim Biophys Acta 2002;1564:21-30
  • Fang JY, Hwang TL, Huang YL. Liposomes as vehicles for enhancing drug delivery via skin routes. Curr Nanosci 2006;2:55-70
  • Willan R. On cutaneous diseases. London: Johnson; 1808
  • Fry L. Centenary review: psoriasis. Br J Dermatol 1988;119:445-61
  • Barker JN. The pathophysiology of psoriasis. Lancet 1991;338:227-30
  • Duvic M. Immunology of AIDS related to psoriasis. J Invest Dermatol 1990;95:38S-40S
  • Stern RS. Psoriasis. Lancet 1997;350:349-53
  • Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;445:866-73
  • Goodfield M, Kownacki S, Berth-Jones J. Double-blind, randomised, multicentre, parallel group study comparing a 1% coal tar preparation (Exorex®) with a 5% coal tar preparation (Alphosyl®) in chronic plaque psoriasis. J Dermatol Treat 2004;15:14-22
  • van de Kerkhof PC. The topical treatment of psoriasis. Clin Exp Dermatol 2005;30:205-8
  • Champion RH, Burton JL, Burns DA, Breathnach SM, Griffiths WAD, Wilkinson JD. Topical therapy: tars. Textbook of Dermatology. Oxford, UK: Blackwell Science; 1998
  • Hansen AM, Poulsen OM, Menne T. Longitudinal study of excretion of metabolites of polycyclic aromatic hydrocarbons in urine from two psoriatic patients. Acta Derm Venereol 1993;73:188-90
  • Schoket B, Horkay I, Kosa A, et al. Formation of DNA adducts in the skin of psoriasis patients, in human skin in organ culture, and in mouse skin and lung following topical application of coal-tar and juniper tar. J Invest Dermatol 1990;94:241-6
  • Schmid MH, Korting HC. Coal tar, pine tar and sulfonated shale oil preparations: comparative activity, efficacy and safety. Dermatology 1996;193:1-5
  • Eads TJ, Saunders WB. Miscellaneous topical agents in comprehensive dermatologic drug therapy. In: Comprehensive Dermatologic Drug Therapy. Wolverton S, editor. Philadelphia; 2001
  • Kist JM, Van Voorhees AS. Narrowband ultraviolet B therapy for psoriasis and other skin disorders. Adv Dermatol 2005;21:235-50
  • Sminkels OQ, Prins M, Veeniiuis RT, et al. Effectiveness and side effects of UVB-phototherapy, dithranol inpatient therapy and a care instruction programme of short contact dithranol in moderate to severe psoriasis. Eur J Dermatol 2004;14:159-65
  • Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999;41:51-9
  • Lebwohl M. Advances in psoriasis therapy. Dermatol Clin 2000;18:13-9
  • Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manage Care Pharm 2004;10:318-25
  • Alvarez-Figueroa MJ, Delgado-Charro MB, Blanco-Mendez J. Passive and iontophoretic transdermal penetration of methotrexate. Int J Pharm 2001;212:101-7
  • McCullough JL, Synder DS, Weinstein GD, Friedland A, Stein B. Factors affecting human percutaneous penetration of methotrexate and its analogues in vitro. J Invest Dermatol 1976;66:103-7
  • Chatterjee DJ, Li WY, Koda RT. Effect of vehicles and penetration enhancers on the in vitro and in vivo percutaneous absorption of methotrexate and edatrexate through hairless mouse skin. Pharm Res 1997;14:1058-65
  • Weinstein GD, McCullough JL, Olsen E. Topical methotrexate therapy for psoriasis. Arch Dermatol 1989;125:227-30
  • Sutton L, Swinehart JM, Cato A, Kaplan AS. A clinical study to determine the efficacy and safety of 1% methotrexate/Azone (MAZ) gel applied topically once daily in patients with psoriasis vulgaris. Int J Dermatol 2001;40:464-7
  • Syed TA, Hadi SM, Qureshi ZA, Nordstrom CG, Ali SM. Management of psoriasis vulgaris with methotrexate 0.25% in a hydrophilic gel: a placebo-controlled, double-blind study. J Cutan Med Surg 2001;5:299-302
  • Singh J, Singh S. Transdermal iontophoresis: effect of penetration enhancer and iontophoresis on drug transport and surface characteristics of human epidermis. Curr Probl Dermatol 1995;22:179-83
  • Alvarez-Figueroa MJ, Blanco-Mendez J. Transdermal delivery of methotrexate: iontophoretic delivery from hydrogels and passive delivery from microemulsions. Int J Pharm 2001;215:57-65
  • Wong TW, Zhao YL, Sen A, Hui SW. Pilot study of topical delivery of methotrexate by electroporation. Br J Dermatol 2005;152:524-30
  • Trotta M, Pattarino F, Gasco MR. Influence of counter ions on the skin permeation of methotrexate from water–oil microemulsions. Pharm Acta Helv 1996;71:135-40
  • Gottlieb AB, Ford RO, Spellman MC. The efficacy and tolerability of clobetasol propionate foam 0.05% in the treatment of mild to moderate plaque-type psoriasis of nonscalp regions. J Cutan Med Surg 2003;7:185-92
  • Del Rosso Do JQ. Combination topical therapy for the treatment of psoriasis. J Drugs Dermatol 2006;5:232-4
  • Huang X, Tanojo H, Lenn J, Cuesico C, Deng H. Impact of vehicle on clobetasol propionate skin permeation and drug distribution in vitro. Poster presented at: American Academy of Dermatology; 2004
  • Goldberg B, Hartdegen R, Presbury D, Smith EH, Yawalkar S. A double-blind, multicenter comparison of 0.05% halobetasol propionate ointment and 0.05% clobetasol propionate ointment in patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991;25:1145-8
  • Mensing H, Korsukewitz G, Yawalkar S. A double-blind, multicenter comparison between 0.05% halobetasol propionate ointment and 0.05% betamethasone dipropionate ointment in chronic plaque psoriasis. J Am Acad Dermatol 1991;25:1166-9
  • Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991;25:1153-6
  • Lebwohl M. Psoriasis. In: Lebwohl MG, Heymann W, Berth-Jones, et al., editors. Treatment of Skin Disease: Comprehensive Treatment Strategies. New York: Mosby International; 2002
  • Rivera AM, Hsu S. Topical halobetasol propionate in the treatment of plaque psoriasis: a review. Am J Clin Dermatol 2005;6:311-6
  • Fresta M, Puglish G. Corticosteroid dermal delivery with skin-lipid liposomes. J Control Rel 1997;44:141-51
  • Korting HC, Zienicke H, Schafer-Korting M, Braun-Falco O. Liposome encapsulation improves efficacy of betamethasone dipropionate in atopic eczema but not in psoriasis vulgaris. Eur J Clin Pharmacol 1990;39:349-51
  • Schmid M-H, Korting HC. Therapeutic progress with topical liposome drugs for skin disease. Adv Drug Deliv Rev 1996;18:335-42
  • Richards HL, Fortune DG, O'Sullivan TM, Main CJ, Griffiths CE. Patients with psoriasis and their compliance with medication. J Am Acad Dermatol 1999;41:581-3
  • Milani M, Antonio Di Molfetta S, Gramazio R, et al. Efficacy of betamethasone valerate 0.1% thermophobic foam in seborrhoeic dermatitis of the scalp: an open-label, multicentre, prospective trial on 180 patients. Curr Med Res Opin 2003;19:342-5
  • Mancuso G, Balducci A, Casadio C, et al. Efficacy of betamethasone valerate foam formulation in comparison with betamethasone dipropionate lotion in the treatment of mild-to-moderate alopecia areata: a multicenter, prospective, randomized, controlled, investigator-blinded trial. Int J Dermatol 2003;42:572-5
  • Müller K, Bendtzen K. 1,25-Dihydroxyvitamin D3 as a natural regulator of human immune functions. J Invest Dermatol Symp Proc 1996;1:68-71
  • Binderup L, Kragballe K. Origin and use of calcipotriol in psoriasis treatment. Rev Contemp Pharmacother 1992;23:401-9
  • Barker JN, Ashton RE, Marks R, Harris RI, Berth-Jones J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999;141:274-8
  • Fogh K, Kragballe K. New vitamin D analogs in psoriasis. Curr Drug Target Inflamm Allergy 2004;3:199-204
  • Staberg B, Roed-Petersen J, Menne T. Efficacy of topical treatment in psoriasis with MC 903, a new vitamin D analogue. Acta Derm Venereol 1989;69:147-50
  • Klaber MR, Hutchinson PE, Pedvis-Leftick A, et al. Comparative effects of calcipotriol solution (50 micrograms/ml) and betamethasone 17-valerate solution (1 mg/ml) in the treatment of scalp psoriasis. Br J Dermatol 1994;131:678-83
  • Tosti A, Piraccini BM, Cameli N, et al. Calcipotriol ointment in nail psoriasis: a controlled double-blind comparison with betamethasone dipropionate and salicylic acid. Br J Dermatol 1998;139:655-9
  • Kaur I, Saraswat A, Kumar B. Comparison of calcipotriol and coal tar in conjunction with sun exposure in chronic plaque psoriasis: a pilot study. J Dermatol 2001;28:448-50
  • Bourke JF, Berth-Jones J, Hutchinson PE. Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris. Clin Exp Dermatol 1993;18:504-6
  • Nielsen PG. Calcipotriol or clobetasol propionate occluded with a hydrocolloid dressing for treatment of nummular psoriasis. Acta Derm Venereol 1993;73:394
  • TV-02 Ointment Research Group. Study on the efficacy TV-02 ointment for psoriasis: results of a double-blind, comparative clinical study of the left and right side with a placebo (ointment base) as a control. Nishinihon J Dermatol 1991;53:1252-61
  • Nishimura M, Hori Y, Nishiyama S, Nakamizo Y. Topical 1alpha,24 (R)-dihydroxyvitamin D3 for the treatment of psoriasis. Review of the literature. Eur J Dermatol 1993;3:255-61
  • Kowalzick L. Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis. Br J Dermatol 2001;144:21-5
  • Lebwohl M, Ast E, Callen JP, et al. Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis. J Am Acad Dermatol 1998;38:705-11
  • Esgleyes-Ribot T, Chandraratna RA, Lew-Kaya DA, Sefton J, Duvic M. Response of psoriasis to a new topical retinoid, AGN 190168. J Am Acad Dermatol 1994;30:581-90
  • Study repot PK-95-022. Pharmacokinetics of AGN 190168 0.1% gel following single-dose and multiple-dose topical administration to healthy subjects. Irvine CA: Allergan; 1995
  • Yamauchi PS, Rizk D, Lowe NJ. Retinoid therapy for psoriasis. Dermatol Clin 2004;22:467-76
  • Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999;107:595-605
  • Veraldi S, Schianchi R. Short-contact therapy with tazarotene in psoriasis vulgaris. Dermatology 2003;206:347-8
  • Tse TW. Use of common Chinese herbs in the treatment of psoriasis. Clin Exp Dermatol 2003;28:469-75
  • Yuan ZZ, Yuan X, Xu ZX. Studies on tabellae indigo naturalis in treatment of psoriasis. J Trad Chin Med 1982;2:306
  • Verucchi G, Calza L, Attard L, Chiodo F. Acute hepatitis induced by traditional Chinese herbs used in the treatment of psoriasis. J Gastroenterol Hepatol 2002;17:1342-3
  • Lin YK, Wong WR, Su Pang JH. Successful treatment of recalcitrant psoriasis with Indigo naturalis ointment. Clin Exp Dermatol 2007;32:99-100
  • Lin YK, Wong WR, Chang YC, et al. The efficacy and safety of topically applied Indigo naturalis ointment in patients with plaque-type psoriasis. Dermatology 2007;214:155-61
  • Liao YH, Chiu HC, Tseng YS, Tsai TF. Comparison of cutaneous tolerance and efficacy of calcitriol 3 μg g-1 ointment and tacrolimus 0.3 mg g-1 ointment in chronic plaque psoriasis involving facial or genitofemoral areas: a double-blind, randomized controlled trial. Br J Dermatol 2007;157:1005-12
  • Perry HO, Soderstrom CW, Schulze RW. The Goeckerman treatment of psoriasis. Arch Dermatol 1968;98:178-82
  • Pittelkow MR, Perry HO, Muller SA, Maughan WZ, O'Brien PC. Skin cancer in patients with psoriasis treated with coal tar. A 25-year follow-up study. Arch Dermatol 1981;117:465-8
  • Gupta G, Long J, Tillman DM. The efficacy of narrowband ultraviolet B phototherapy in psoriasis using objective and subjective outcome measures. Br J Dermatol 1999;140:887-90
  • Trehan M, Taylor CR. Medium-dose 308-nm excimer laser for the treatment of psoriasis. J Am Acad Dermatol 2002;47:701-8
  • Gasparro FP, Liao B, Foley PJ, Wang XM, McNiff JM. Psoralen photochemotherapy, clinical efficacy, and photomutagenicity: the role of molecular epidemiology in minimizing risks. Environ Mol Mutagen 1998;31:105-12
  • Isaacs ST, Shen CJ, Hearst JE, Rpoport H. Synthesis and characterization of new psoralen derivatives with superior photoreactivity with DNA and RNA. Biochemistry 1997;16:1058-64
  • Gorham H. Treatment of psoriatic arthropathy by PUVA. Physiotherapy 1980;66:40
  • Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA follow-up study. J Natl Cancer Inst 1998;90:1278-84
  • Stern RS, Nichols KT, Vakeva LH. Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow-up study. N Engl J Med 1997;336:1041-5
  • Fritsch C, Verwohlt B, Bolsen K, Ruzicka T, Goerz G. Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism. Arch Dermatol Res 1996;288:517-21
  • Wolf P, Rieger E, Kerl H. Topical photodynamic therapy with endogenous porphyrins after application of 5-aminolevulinic acid. An alternative treatment modality for solar keratoses, superficial squamous cell carcinomas, and basal cell carcinomas? J Am Acad Dermatol 1993;28:17-21
  • Boehncke WH, Sterry W, Kaufmann R. Treatment of psoriasis by topical photodynamic therapy with polychromatic light. Lancet 1994;343:801
  • Stringer MR, Collins P, Robinson DJ, Stables GI, Sheehan-Dare RA. The accumulation of protoporphyrin IX in plaque psoriasis after topical application of 5-aminolevulinic acid indicates a potential for superficial photodynamic therapy. J Invest Dermatol 1996;107:76-81
  • Peng Q, Berg K, Moan J, Kongshaug M, Nesland JM. 5-Aminolevulinic acid-based photodynamic therapy: principles and experimental research. Photochem Photobiol 1997;65:235-51
  • Fang JY, Lee WR, Shen SC, Fang YP, Hu CH. Enhancement of topical 5-aminolaevulinic acid delivery by erbium:YAG laser and microdermabrasion: a comparison with iontophoresis and electroporation. Br J Dermatol 2004;151:132-40
  • Moan J, Berg K, Gadmar OB, Iani V, Ma L, Juzenas P. The temperature dependence of protoporphyrin IX production in cells and tissues. Photochem Photobiol 1999;70:669-73
  • De Rosa FS, Marchetti JM, Thomazini JA, Tedesco AC, Bentley MV. A vehicle for photodynamic therapy of skin cancer: influence of dimethylsulphoxide on 5-aminolevulinic acid in vitro cutaneous permeation and in vivo protoporphyrin IX accumulation determined by confocal microscopy. J Control Rel 2000;65:359-66
  • Lopez RF, Bentley MV, Delgado-Charro MB, Guy RH. Iontophoretic delivery of 5-aminolevulinic acid (ALA): effect of pH. Pharm Res 2001;18:311-5
  • Lieb S, Szeimies RM, Lee G. Self-adhesive thin films for topical delivery of 5-aminolevulinic acid. Eur J Pharm Biopharm 2002;53:99-106
  • Auner BG, Valenta C, Hadgraft J. Influence of lipophilic counter-ions in combination with phloretin and 6-ketocholestanol on the skin permeation of 5-aminolevulinic acid. Int J Pharm 2003;255:109-16
  • Shen SC, Lee WR, Fang YP, Hu CH, Fang JY. In vitro percutaneous absorption and in vivo protoporphyrin IX accumulation in skin and tumors after topical 5-aminolevulinic acid application with enhancement using an erbium: YAG laser. J Pharm Sci 2006;95:929-38
  • Boehncke WH, Elshorst-Schmidt T, Kaufmann R. Systemic photodynamic therapy is a safe and effective treatment for psoriasis. Arch Dermatol 2000;136:271-2
  • Ibbotson SH. Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of skin conditions other than non-melanoma skin cancer. Br J Dermatol 2002;146:178-88
  • Wachter E, Dees C, Harkins J, et al. Topical rose Bengal: pre-clinical evaluation of pharmacokinetics and safety. Lasers Surg Med 2003;32:101-10
  • van de Kerkhof PC, Vissers WH. Established treatments of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:145-56
  • Danielsen AG, Heidenheim M, Wulf HC. Crude coal tar treatment every day versus every other day for plaque psoriasis. Acta Derm Venereol 2001;81:221-2
  • De Jong EMGJ, Mørk NJ, Seijger MMB, et al. The combination of calcipotriol and methotrexate compared with methotrexate and vehicle in psoriasis: results of a multicentre placebo-controlled randomized trial. Br J Dermatol 2003;148:318-25
  • Ben-Shabat S, Benisty R, Wormser U, Sintov AC. Vitamin D3-based conjugates for topical treatment of psoriasis: synthesis, antiproliferative activity, and cutaneous penetration studies. Pharm Res 2005;22:50-7
  • Douglas WS, Poulin Y, Decroix J, et al. A new calcipotriol/betamethasone formulation with rapid onset of action was superior to monotherapy with betamethasone dipropionate or calcipotriol in psoriasis vulgaris. Acta Derm Venereol 2002;82:131-5
  • Guenther L, van de Kerkhof PC, Snellman E, et al. Efficacy and safety of a new combination of calcipotriol and betamethasone dipropionate (once or twice daily) compared to calcipotriol (twice daily) in the treatment of psoriasis vulgaris: a randomized, double-blind, vehicle-controlled clinical trial. Br J Dermatol 2002;147:316-23
  • Kaufmann R, Bibby AJ, Bissonnette R, et al. A new calcipotriol/betamethasone dipropionate formulation (Daivobet®) is an effective once-daily treatment for psoriasis vulgaris. Dermatology 2002;205:389-93
  • Papp KA, Guenther L, Boyden B, et al. Early onset of action and efficacy of a combination of calcipotriene and betamethasone dipropionate in the treatment of psoriasis. J Am Acad Dermatol 2003;48:48-54
  • Ortonne JP, Kaufmann R, Lecha M, Goodfield M. Efficacy of treatment with calcipotriol/betamethasone dipropionate followed by calcipotriol alone compared with tacalcititol for the treatment of psoriasis vulgaris: a randomised, double blind trial. Dermatology 2004;209:308-13
  • Bowman PH, Maloney JE, Koo JY. Combination of calcipotriene (Dovonex®) ointment and tazarotene (Tazorac®) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study. J Am Acad Dermatol 2002;46:907-13
  • van de Kerkhof PC. Update on retinoid therapy of psoriasis in: an update on the use of retinoids in dermatology. Dermatol Ther 2006;19:252-63
  • Behrens S, Grundmann-Kollmann M, Schiener R, Peter RU, Kerscher M. Combination phototherapy of psoriasis with narrow-band UVB irradiation and topical tazarotene gel. J Am Acad Dermatol 2000;42:493-5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.